Striatal dopamine transporter alterations in ADHD: Pathophysiology or adaptation to psychostimulants? A meta-analysis

American Journal of Psychiatry

Volumn 169, Issue 3, 2012, Pages 264-272

  Fusar Poli, Paolo ^a,b,c   Rubia, Katya ^a,b,c   Rossi, Giorgio ^a,b,c   Sartori, Giuseppe ^a,b,c   Balottin, Umberto ^a,b,c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF PAVIA   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE TRANSPORTER; PSYCHOSTIMULANT AGENT;

ADAPTATION; ATTENTION DEFICIT DISORDER; CORPUS STRIATUM; DENSITY; DRUG EXPOSURE; HUMAN; META ANALYSIS (TOPIC); PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REGRESSION ANALYSIS; REVIEW; SENSITIVITY ANALYSIS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYSTEMATIC REVIEW;

EID: 84858970633     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2011.11060940     Document Type: Review

References (63)

1. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed (DSM-IV). Washington, DC, APA, 1994
2. Polanczyk G, Moffitt TE, Arseneault L, Cannon M, Ambler A, Keefe RS, Houts R, Odgers CL, Caspi A: Etiological and clinical features of childhood psychotic symptoms: results from a birth cohort. Arch Gen Psychiatry 2010; 67:328-338
3. Biederman J, Petty C, Faraone SV, Hirshfeld-Becker DR, Henin A, Rauf A, Scott M, Pollack M, Rosenbaum JF: Childhood antecedents to panic disorder in referred and nonreferred adults. J Child Adolesc Psychopharmacol 2005; 15:549-561 (Pubitemid 41434360)
4. Cubillo A, Rubia K: Structural and functional brain imaging in adult attention-deficit/hyperactivity disorder. Expert Rev Neurother 2010; 10:603-620
5. Rubia K: "Cool" inferior frontostriatal dysfunction in attention-deficit/ hyperactivity disorder versus "hot" ventromedial orbitofrontal- limbic dysfunction in conduct disorder: a review. Biol Psychiatry 2011; 69(12):e69-87
6. Madras BK, Miller GM, Fischman AJ: The dopamine transporter and attention-deficit/hyperactivity disorder. Biol Psychiatry 2005; 57:1397-1409 (Pubitemid 40798561)
7. Konrad K, Eickhoff SB: Is the ADHD brain wired differently? a review on structural and functional connectivity in attention deficit hyperactivity disorder. Hum Brain Mapp 2010; 31:904-916
8. Valera EM, Faraone SV, Murray KE, Seidman LJ: Meta-analysis of structural imaging findings in attention-deficit/hyperactivity disorder. Biol Psychiatry 2007; 61:1361-1369 (Pubitemid 46855763)
9. Nakao T, Radua J, Rubia K, Mataix-Cols D: Gray matter volume abnormalities in ADHD: voxel-based meta-analysis exploring the effects of age and stimulant medication. Am J Psychiatry 2011; 168:1154-1163
10. Volkow ND, Wang GJ, Kollins SH, Wigal TL, Newcorn JH, Telang F, Fowler JS, Zhu W, Logan J, Ma Y, Pradhan K, Wong C, Swan son JM: Evaluating dopamine reward pathway in ADHD: clinical implications. JAMA 2009; 302:1084-1091
11. Holt DJ, Graybiel AM, Saper CB: Neurochemical architecture of the human striatum. J Comp Neurol 1997; 384:1-25 (Pubitemid 27280221)
12. Volkow ND, Wang GJ, Fowler JS, Ding YS: Imaging the effects of methylphenidate on brain dopamine: new model on its therapeutic actions for attention-deficit/hyperactivity disorder. Biol Psychiatry 2005; 57:1410-1415 (Pubitemid 40798562)
13. Gizer IR, Ficks C, Waldman ID: Candidate gene studies of ADHD: a meta-analytic review. Hum Genet 2009; 126:51-90
14. Piccini PP: Dopamine transporter: basic aspects and neuroimaging. Mov Disord 2003; 18(suppl 7):S3-S8
15. Meisenzahl EM, Schmitt GJ, Scheuerecker J, Moller HJ: The role of dopamine for the pathophysiology of schizophrenia. Int Rev Psychiatry 2007; 19:337-345 (Pubitemid 47206979)
16. Dougherty DD, Bonab AA, Spencer TJ, Rauch SL, Madras BK, Fischman AJ: Dopamine transporter density in patients with attention deficit hyperactivity disorder. Lancet 1999; 354:2132-2133 (Pubitemid 30008900)
17. Fusar-Poli P, Meyer-Lindenberg A: Striatal presynaptic dopamine in schizophrenia, part I: meta-analysis of dopamine active transporter density. Schizophr Bull (in press)
18. van Dyck CH, Quinlan DM, Cretella LM, Staley JK, Malison RT, Baldwin RM, Seibyl JP, Innis RB: Unaltered dopamine transporter availability in adult attention deficit hyperactivity disorder. Am J Psychiatry 2002; 159:309-312 (Pubitemid 34126913)
19. Zimmer L: Positron emission tomography neuroimaging for a better understanding of the biology of ADHD. Neuropharmacology 2009; 57:601-607
20. Spencer TJ, Biederman J, Madras BK, Faraone SV, Dougherty DD, Bonab AA, Fischman AJ: In vivo neuroreceptor imaging in attention-deficit/hyperactivity disorder: a focus on the dopamine transporter. Biol Psychiatry 2005; 57:1293-1300 (Pubitemid 40798548)
21. Krause KH, Dresel SH, Krause J, la Fougere C, Ackenheil M: The dopamine transporter and neuroimaging in attention deficit hyperactivity disorder. Neurosci Biobehav Rev 2003; 27:605-613 (Pubitemid 37414909)
22. van der Kooij MA, Glennon JC: Animal models concerning the role of dopamine in attention-deficit hyperactivity disorder. Neurosci Biobehav Rev 2007; 31:597-618 (Pubitemid 46527883)
23. Moher D, Liberati A, Tetzlaff J, Altman DG: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009; 339:b2535
24. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF, QUOROM group: Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Br J Surg 2000; 87:1448-1454
25. Juni P, Witschi A, Bloch R, Egger M: The hazards of scoring the quality of clinical trials for meta-analysis. JAMA 1999; 282:1054-1060 (Pubitemid 29436453)
26. Paulson JF, Bazemore SD: Prenatal and postpartum depression in fathers and its association with maternal depression: a meta-analysis. JAMA 2010; 303:1961-1969
27. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB, Meta-Analysis of Observational Studies in Epidemiology (MOOSE) Group: Meta-analysis of observational studies in epidemiology: a proposal for reporting. JAMA 2000; 283:2008-2012 (Pubitemid 30214957)
28. Hedges L, Holkin I: Statistical Methods for Meta-Analysis. New York, Academic, 1985
29. Cooper H, Hedges L, Valentine J (eds): Handbook of Research Synthesis and Meta-Analysis. New York, Russell Sage Foundation, 2009
30. Lipsey M, Wilson D: Practical Meta-Analysis. Thousand Oaks, Calif, Sage Publications, 2000
31. Egger M, Davey Smith G, Schneider M, Minder C: Bias in meta- analysis detected by a simple, graphical test. BMJ 1997; 315:629-634 (Pubitemid 27387172)
32. Orwin R: A fail-safe N for effect size in meta-analysis. J Edu Stat 1983; 8:157-159
33. Cheon KA, Ryu YH, Namkoong K, Kim CH, Kim JJ, Lee JD: Dopamine transporter density of the basal ganglia assessed with [123I]IPT SPECT in drug-naive children with Tourette's disorder. Psychiatry Res 2004; 130:85-95 (Pubitemid 38221560)
34. Jucaite A, Fernell E, Halldin C, Forssberg H, Farde L: Reduced midbrain dopamine transporter binding in male adolescents with attention-deficit/ hyperactivity disorder: association between striatal dopamine markers and motor hyperactivity. Biol Psychiatry 2005; 57:229-238 (Pubitemid 40187366)
35. la Fougere C, Krause J, Krause KH, Josef Gildehaus F, Hacker M, Koch W, Hahn K, Tatsch K, Dresel S: Value of 99mTc-TRODAT-1. SPECT to predict clinical response to methylphenidate treatment in adults with attention deficit hyperactivity disorder. Nucl Med Commun 2006; 27:733-737 (Pubitemid 44213031)
36. Larisch R, Sitte W, Antke C, Nikolaus S, Franz M, Tress W, Müller H-W: Striatal dopamine transporter density in drug naive patients with attention-deficit/hyperactivity disorder. Nucl Med Commun 2006; 27:267-270 (Pubitemid 44391815)
37. Spencer TJ, Biederman J, Madras BK, Dougherty DD, Bonab AA, Livni E, Meltzer PC, Martin J, Rauch S, Fischman AJ: Further evidence of dopamine transporter dysregulation in ADHD: a controlled PET imaging study using altropane. Biol Psychiatry 2007; 62:1059-1061 (Pubitemid 47562362)
38. Hesse S, Ballaschke O, Barthel H, Sabri O: Dopamine transporter imaging in adult patients with attention-deficit/hyperactivity disorder. Psychiatry Res 2009; 171:120-128
39. Higgins J, Thompson S: Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21:1539-1558 (Pubitemid 34746062)
40. Hazell P: The challenges to demonstrating long-term effects of psychostimulant treatment for attention-deficit/hyperactivity disorder. Curr Opin Psychiatry 2011; 24:286-290
41. Varrone A, Halldin C: Molecular imaging of the dopamine transporter. J Nucl Med 2010; 51:1331-1334
42. Vles JS, Feron FJ, Hendriksen JG, Jolles J, van Kroonenburgh MJ, Weber WE: Methylphenidate down-regulates the dopamine receptor and transporter system in children with attention deficit hyperkinetic disorder (ADHD). Neuropediatrics 2003; 34:77-80 (Pubitemid 36597126)
43. Krause J, la Fougere C, Krause KH, Ackenheil M, Dresel SH: Influence of striatal dopamine transporter availability on the response to methylphenidate in adult patients with ADHD. Eur Arch Psychiatry Clin Neurosci 2005; 255:428-431 (Pubitemid 43029831)
44. Ludolph AG, Kassubek J, Schmeck K, Glaser C, Wunderlich A, Buck AK, Reske SN, Fegert JM, Mottaghy FM: Dopaminergic dysfunction in attention deficit hyperactivity disorder (ADHD), differences between pharmacologically treated and never treated young adults: a 3,4-dihdroxy-6-[18F]fluorophenyl-l-alanine PET study. Neuroimage 2008; 41:718-727
45. Volkow N, Wang GJ, Fowler J, Logan J, Gerasimov M, Maynard L, Ding Y, Gatley SJ, Gifford A, Franceschi D: Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. J Neurosci 2001; 21(2):RC121
46. Forssberg H, Fernell E, Waters S, Waters N, Tedroff J: Altered pattern of brain dopamine synthesis in male adolescents with attention deficit hyperactivity disorder. Behav Brain Funct 2006; 2:40
47. Volkow ND, Wang GJ, Newcorn J, Telang F, Solanto MV, Fowler JS, Logan J, Ma Y, Schulz K, Pradhan K, Wong C, Swanson JM: Depressed dopamine activity in caudate and preliminary evidence of limbic involvement in adults with attention-deficit/ hyperactivity disorder. Arch Gen Psychiatry 2007; 64:932-940 (Pubitemid 47230617)
48. Wang G-J, Volkow N, Wigal T, Kollins S, Newcorn J, Telang F, Logan J, Wong C, Fowler JS, Swanson JM: Chronic treatment with methylphenidate increases dopamine transporter density in patients with attention deficit hyperactive disorder. J Nucl Med 2009; 50(suppl 2):1283
49. Schmitt KC, Reith ME: Regulation of the dopamine transporter: aspects relevant to psychostimulant drugs of abuse. Ann NY Acad Sci 2010; 1187:316-340
50. Rubia K, Halari R, Cubillo A, Mohammad AM, Brammer M, Taylor E: Methylphenidate normalises activation and functional connectivity deficits in attention and motivation networks in medication-naive children with ADHD during a rewarded continuous performance task. Neuropharmacology 2009; 57:640-652
51. Rubia K, Halari R, Cubillo A, Smith AB, Mohammad AM, Brammer M, Taylor E: Methylphenidate normalizes fronto-striatal underactivation during interference inhibition in medication-naive boys with attention-deficit hyperactivity disorder. Neuropsychopharmacology 2011; 36:1575-1586
52. Rubia K, Halari R, Mohammad AM, Taylor E, Brammer M: Methylphenidate normalizes frontocingulate underactivation during error processing in attention-deficit hyperactivity disorder. Biol Psychiatry 2011; 70:255-262
53. Rubia K, Halari R, Christakou A, Taylor E: Impulsiveness as a timing disturbance: neurocognitive abnormalities in attention-deficit hyperactivity disorder during temporal processes and normalization with methylphenidate. Philos Trans R Soc Lond B Biol Sci 2009; 364:1919-1931
54. Shafritz KM, Marchione KE, Gore JC, Shaywitz SE, Shaywitz BA: The effects of methylphenidate on neural systems of attention in attention deficit hyperactivity disorder. Am J Psychiatry 2004; 161:1990-1997 (Pubitemid 39441398)
55. Bush G: Neuroimaging of attention deficit hyperactivity disorder: can new imaging findings be integrated in clinical practice? Child Adolesc Psychiatr Clin N Am 2008; 17:385-404
56. Sobel LJ, Bansal R, Maia TV, Sanchez J, Mazzone L, Durkin K, Liu J, Hao X, Ivanov I, Miller A, Greenhill LL, Peterson BS: Basal ganglia surface morphology and the effects of stimulant medications in youth with attention deficit hyperactivity disorder. Am J Psychiatry 2010; 167:977-986
57. Semrud-Clikeman M, Pliszka SR, Lancaster J, Liotti M: Volumetric MRI differences in treatment-naive vs chronically treated children with ADHD. Neurology 2006; 67:1023-1027 (Pubitemid 44454597)
58. Krause J: SPECT and PET of the dopamine transporter in attention- deficit/hyperactivity disorder. Expert Rev Neurother 2008; 8:611-625
59. Hannestad J, Gallezot JD, Planeta-Wilson B, Lin SF, Williams WA, van Dyck CH, Malison RT, Carson RE, Ding YS: Clinically relevant doses of methylphenidate significantly occupy norepinephrine transporters in humans in vivo. Biol Psychiatry 2010; 68:854-860
60. Bowton E, Saunders C, Erreger K, Sakrikar D, Matthies HJ, Sen N, Jessen T, Colbran RJ, Caron MG, Javitch JA, Blakely RD, Galli A: Dysregulation of dopamine transporters via dopamine D2 autoreceptors triggers anomalous dopamine efflux associated with attention-deficit hyperactivity disorder. J Neurosci 2010; 30:6048-6057
61. Weiss S, Tzavara ET, Davis RJ, Nomikos GG, McIntosh JM, Giros B, Martres MP: Functional alterations of nicotinic neurotransmission in dopamine transporter knock-out mice. Neuropharmacology 2007; 52:1496-1508 (Pubitemid 46678082)
62. Grizenko N, Paci M, Joober R: Is the inattentive subtype of ADHD different from the combined/hyperactive subtype? J Atten Disord 2010; 13:649-657
63. Roessner V, Sagvolden T, Dasbanerjee T, Middleton FA, Faraone SV, Walaas SI, Becker A, Rothenberger A, Bock N: Methylphenidate normalizes elevated dopamine transporter densities in an animal model of the attention-deficit/ hyperactivity disorder combined type, but not to the same extent in one of the attention-deficit/hyperactivity disorder inattentive type. Neuroscience 2010; 167:1183-1191